AKROacquired
Akero Therapeutics, Inc.
Biopharma developer (SEC filing verified)·Phase 3·CEO: Chief Executive Officer
Infectious DiseaseMetabolicGastroenterology
Run Akero Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Akero Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Regulatory
Governance
Frequently asked questions
Who is the CEO of Akero Therapeutics, Inc.?
Chief Executive Officer is the chief executive officer of Akero Therapeutics, Inc. (AKRO).
What therapeutic areas does Akero Therapeutics, Inc. focus on?
Akero Therapeutics, Inc. develops therapies across Infectious Disease, Metabolic, Gastroenterology.
923 companies304,839 SEC filings22,636 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.